QCI Secondary Analysis
How decentralized and small labs can adopt high-throughput NGS analysis with limited time and resource investment
78 views
To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.
In this webinar, attendees will learn how QCI Secondary Analysis:
. Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
. Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
. Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.
Related videos
QCI Secondary Analysis
Introducing QCI Secondary Analysis
Introducing QCI Secondary Analysis, a new cloud-based service for NGS...